News and events
![](https://haystackmrd.com/wp-content/uploads/2024/04/Haystack-MRD-news-featured-image-banner.jpg)
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development
![](https://haystackmrd.com/wp-content/uploads/2024/04/Haystack-MRD-news-featured-image-banner.jpg)
Haystack technology in action at ASCO 2024!
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT’s
![](https://haystackmrd.com/wp-content/uploads/2024/04/Haystack-MRD-news-featured-image-banner.jpg)
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT’s
![](https://haystackmrd.com/wp-content/uploads/2024/04/Haystack-MRD-news-featured-image-banner.jpg)
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus’ TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development
![](https://haystackmrd.com/wp-content/uploads/2024/04/Haystack-MRD-news-featured-image-banner.jpg)
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT’s
![](https://haystackmrd.com/wp-content/uploads/2024/04/Haystack-MRD-news-featured-image-banner.jpg)
Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology’s industry-leading personalized MRD technology (Haystack MRD™) to help evaluate therapeutic response and provide molecular insights for
Recent events
![](https://haystackmrd.com/wp-content/uploads/2024/05/ASCO-2024.png)
American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual
![](https://haystackmrd.com/wp-content/uploads/2024/04/AACR-2024-featured-banner-image.png)
American Association for Cancer Research 2024
Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual
![](https://haystackmrd.com/wp-content/uploads/2024/04/ASCO-GI-.png)
ASCO Gastrointestinal Cancers Symposium 2024
Haystack Oncology, a Quest Diagnostics® company, will be attending the 2024 American Society of Clinical Oncology Gastrointestinal Cancers symposium (ASCO GI), which will be held January 18–20, 2024, in San